UY39477A - Compuestos espiro heterocíclicos y métodos de uso - Google Patents

Compuestos espiro heterocíclicos y métodos de uso

Info

Publication number
UY39477A
UY39477A UY0001039477A UY39477A UY39477A UY 39477 A UY39477 A UY 39477A UY 0001039477 A UY0001039477 A UY 0001039477A UY 39477 A UY39477 A UY 39477A UY 39477 A UY39477 A UY 39477A
Authority
UY
Uruguay
Prior art keywords
methods
cancer
spiro compounds
heterocyclic spiro
compounds
Prior art date
Application number
UY0001039477A
Other languages
English (en)
Inventor
Van Ma Vu
Abhisek Banerjee
Chu-Moyer Margaret
Dongcheng Dai
Josephine Eshon
David Huang
Heejun Lee
Patricia Lopez
Francesco Manoni
M Medina Jose
Charles Stellwagen John
Wenhan Zhang
Kai Zhu
Alan Lanman Brian
A Tamayo Nuria
R Kaller Matthew
J Pickrell Alexander
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY39477A publication Critical patent/UY39477A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación proporciona compuestos de Fórmula I que tienen actividad como inhibidores de la proteína mutante KRAS G12C. Esta divulgación también proporciona composiciones farmacéuticas que comprenden los compuestos, usos y métodos para tratar determinados trastornos, tales como el cáncer, que incluyen, pero sin limitación, cáncer de pulmón, cáncer de páncreas y cáncer colorrectal.
UY0001039477A 2020-10-20 2021-10-19 Compuestos espiro heterocíclicos y métodos de uso UY39477A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2020122197 2020-10-20

Publications (1)

Publication Number Publication Date
UY39477A true UY39477A (es) 2022-05-31

Family

ID=81291543

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039477A UY39477A (es) 2020-10-20 2021-10-19 Compuestos espiro heterocíclicos y métodos de uso

Country Status (10)

Country Link
US (1) US20240059703A1 (es)
EP (1) EP4232444A4 (es)
JP (1) JP2023545545A (es)
AR (1) AR123848A1 (es)
AU (1) AU2021363262A1 (es)
CA (1) CA3198809A1 (es)
MX (1) MX2023004518A (es)
TW (1) TW202233629A (es)
UY (1) UY39477A (es)
WO (1) WO2022083569A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
AR125787A1 (es) 2021-05-05 2023-08-16 Revolution Medicines Inc Inhibidores de ras
PE20240088A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras
US20240293558A1 (en) 2021-06-16 2024-09-05 Erasca, Inc. Kras inhibitor conjugates
WO2024102421A2 (en) 2022-11-09 2024-05-16 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
CN115594664B (zh) * 2022-11-25 2023-02-24 英矽智能科技(上海)有限公司 一类螺环衍生物作为kif18a抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
GB201504565D0 (en) * 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
CN107814792B (zh) * 2016-09-14 2021-08-10 中国科学院上海药物研究所 一类喹唑啉衍生物、其组合物及用途
AU2019312670A1 (en) * 2018-08-01 2021-02-04 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
MX2021004624A (es) * 2018-10-24 2021-05-27 Araxes Pharma Llc Derivados de 2-(2-acriloil-2,6-diazaspiro[3.4]octan-6-il)-6-(1h-in dazol-4-il)-benzonitrilo y compuestos relacionados como inhibidores de la proteina kras mutante g12c para inhibir metastasis de tumor.
EP3887373A1 (en) * 2018-11-29 2021-10-06 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
WO2020177629A1 (zh) * 2019-03-01 2020-09-10 劲方医药科技(上海)有限公司 螺环取代的嘧啶并环类化合物，其制法与医药上的用途

Also Published As

Publication number Publication date
EP4232444A1 (en) 2023-08-30
WO2022083569A1 (en) 2022-04-28
MX2023004518A (es) 2023-06-19
TW202233629A (zh) 2022-09-01
AR123848A1 (es) 2023-01-18
US20240059703A1 (en) 2024-02-22
AU2021363262A1 (en) 2023-06-08
EP4232444A4 (en) 2024-09-11
CA3198809A1 (en) 2022-04-28
JP2023545545A (ja) 2023-10-30

Similar Documents

Publication Publication Date Title
UY39477A (es) Compuestos espiro heterocíclicos y métodos de uso
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
ECSP20079887A (es) Derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores pd-l1
CO2023007504A2 (es) Derivados de carboxamida tricíclica como inhibidores de prmt5
CL2023001738A1 (es) Inhibidores de prmt5
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
CL2021001722A1 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
EA201792214A1 (ru) Соединения замещенного хиназолина
CL2021001721A1 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
CO2023010023A2 (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
UY37225A (es) Inhibidores del potenciador del homólogo zeste 2 campo de la invención
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
ECSP24035717A (es) Compuestos de quinolina como inhibidores de kras
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
EA201791179A1 (ru) Дейтерированный триазолопиридазин в качестве модулятора киназы
CO2022017969A2 (es) Compuestos de imidazopiridazina con actividad como inhibidores de alk2
EA202191541A1 (ru) ЗАМЕЩЕННЫЕ ФОСФОРОРГАНИЧЕСКИМИ ГРУППАМИ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras
AR117459A1 (es) Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos